Option Care Health, Inc. (OPCH)

On our long-short equity desk, OPCH has been a fascinating rollercoaster. The 40% pullback since January created an exaggerated reaction to the Stelara patent loss. With Q2 revenue hitting $1.44 billion and adjusted EPS coming in at $0.45—beating consensus—management's ability to hold FY26 guidance steady shows underlying operational resilience. However, market share concerns and credibility friction from earlier quarters suggest we should keep positions tactical until chronic portfolio headwinds completely stabilize.

As a risk manager tracking downside exposure, the fundamental divergence between the acute and chronic portfolios is critical. Acute therapy organic growth remains exceptionally strong in the high single digits, cushioning the blow from the CID portfolio pressure that's shaving roughly 600 basis points off 2026 revenue. The strong operating cash flow of $184 million in Q2 provides a reliable cushion, but lingering insurance coverage switches require close monitoring.

Evaluating the underlying therapy mix, the strength in acute care is compensating for the CID portfolio headwinds. As chronic revenue gradually improves and stabilizes, the gross profit drag of $55 million associated with CID pressures becomes easier to digest. Analysts questioning management during the Q2 call focused heavily on visibility, but execution on SGandA efficiency keeps the bottom-line metrics intact.

From a clinical operations standpoint, the shift in alternate-site infusion dynamics highlights the importance of execution. Option Care Health remains the nation's largest independent home and alternate site infusion provider, which gives them unique leverage. Even with the gross profit hit from Stelara, their strategic cost reductions and SGandA savings are keeping Adjusted EBITDA within the tightened $480 million to $495 million band for the full year.

Watching the options flow and social sentiment on StockTwits and Twitter, retail and institutional participants remain deeply divided. The Q1 selloff wiped out over 30% of market value before Q2's better-than-expected print catalyzed a relief rally. Insider buying and the $150 million share repurchase program executed in Q2 signal that leadership believes the equity is undervalued at roughly 15x FY26E EPS.